Sign In
Buy TARS
$58.76
+1.35 (+2.35%)
At Close: Jun 03, 2026
Unique and memorable campaign intended to educate consumers about Demodex blepharitis and XDEMVY, the first and only FDA approved solution for the disease
Tarsus Announces Pricing of $100.0 Million Public Offering
12:07am, Friday, 01'st Mar 2024
IRVINE, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”), whose mission is to focus on unmet needs and apply proven science an
Tarsus Announces Proposed $100.0 Million Public Offering
04:37pm, Thursday, 29'th Feb 2024
IRVINE, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”), whose mission is to focus on unmet needs and apply proven science and
Here's Why Tarsus Pharmaceuticals, Inc. (TARS) is a Great Momentum Stock to Buy
01:01pm, Wednesday, 28'th Feb 2024
Does Tarsus Pharmaceuticals, Inc. (TARS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Tarsus Pharmaceuticals, Inc. (TARS) Q4 2023 Earnings Call Transcript
12:09pm, Tuesday, 27'th Feb 2024
Tarsus Pharmaceuticals, Inc. (TARS) Q4 2023 Earnings Call Transcript
Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Achievements
06:00am, Tuesday, 27'th Feb 2024
Launched XDEMVY ® (lotilaner ophthalmic solution) 0.25%, for the treatment of Demodex blepharitis and generated fourth quarter net product sales of $13.1 million, and $14.7 million in the first four
TP-05 demonstrated tolerability and statistically significant tick mortality, suggesting potential for on-demand Lyme disease prophylaxis TP-05 demonstrated tolerability and statistically significant
Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024
05:00pm, Tuesday, 20'th Feb 2024
IRVINE, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize tre
Tarsus Pharmaceuticals, Inc. (TARS) Moves 8.5% Higher: Will This Strength Last?
05:11am, Tuesday, 30'th Jan 2024
Tarsus Pharmaceuticals, Inc. (TARS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into furth
Tarsus Pharmaceuticals: 3 Clinical Catalysts In The Next 4 Months, Xdemvy Launch Underway
12:09pm, Monday, 04'th Dec 2023
TARS has launched a new drug, Xdemvy, for the treatment of Demodex blepharitis, with net product sales of $1.7M in the first five weeks following launch. TARS has readouts from three clinical trials d
Tarsus Pharmaceuticals, Inc. (TARS) Q3 2023 Earnings Call Transcript
06:59pm, Friday, 10'th Nov 2023
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS ) Q3 2023 Results Conference Call November 9, 2023 4:30 PM ET Company Participants David Nakasone - Head, IR Bobak Azamian - Chairman, CEO Aziz Mottiwala - CC
Tarsus to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023
06:35pm, Wednesday, 01'st Nov 2023
IRVINE, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize tre
Rare Stock Picks In September 2023 - From 32 Discerning Analysts
11:25am, Friday, 06'th Oct 2023
Welcome to another installment of our monthly Rare Buy article where we highlight September investment picks you may have missed. As you know some Seeking Alpha analysts are more discerning by nature.
Tarsus Pharmaceuticals: Worthy Of A Small Bet
08:36am, Monday, 04'th Sep 2023
Tarsus Pharmaceuticals has received FDA approval for its lotilaner ophthalmic solution for the treatment of Demodex blepharitis. The company just launched this product known by the brand name Xdemvy a
Tarsus to Present at Upcoming Investor Conferences
04:30pm, Wednesday, 30'th Aug 2023
IRVINE, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize tre
